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Abstract: Corticosteroids are currently the first line of treatment for
patients with atopic dermatitis. In the pediatric population however, the
potential impact of adrenal suppression is always an important safety con-
cern. Twenty boys and girls, 5–12 years of age, with normal adrenal function
and a history of atopic dermatitis were maximally treated three times daily
with a lipid-rich, moisturizing formulation of hydrocortisone butyrate 0.1% for
up to 4 weeks. At the conclusion of the 4-week treatment period, cosyntropin
injection stimulation testing showed no evidence of adrenal suppression. In
addition, the therapy was noted to be highly efficacious, with a clinical suc-
cess rate of 80% (Physician Global Score of (0) clear or (1) almost clear). No
local side effects associated with prolonged use of topical corticosteroids
were reported. In summary, this study supports the contention that this
lipid-rich, moisturizing formulation of hydrocortisone butyrate 0.1% was a
well-tolerated and beneficial treatment for atopic dermatitis, demonstrating
no adrenal suppression in the pediatric population aged 5–12 years. The
relevance of these findings for children below 5 years of age, because of
difference in body mass/surface area ratios, remains to be determined.
Effective management of chronic, recurrent inflam-
matory diseases of the skin in children can reduce the
severity and duration of intermittent flare-ups, and
contribute to a quality of life comparable with that of
individuals unaffected by disease. Estimates of the pre-
valence of atopic dermatitis (AD)vary from10%to17%
(1,2), with 87% of children with the disease exhibiting
signs and symptoms by 5 years of age (3). In many cases
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the first-line therapy for the management of AD exac-
erbations is topical corticosteroids (4). In fact, as per the
American Academy of Dermatology Guidelines for the
treatment of AD, topical steroids are the class of therapy
by which other therapies are measured for the treatment
of this disease (5). Class IV and/orVmid-potency topical
steroids are efficacious in the treatment of AD in pedi-
atric populations; however, the potential impact on
adrenal suppression has not been well characterized.
Topical hydrocortisonebutyrate 0.1%(HB0.1%)has
been found to be well tolerated and beneficial for the
treatment of AD in adults, and has been available in a
variety of dosage formulations (6). However, the poten-
tial for adverse systemic effects is greater in children
compared with adults because of the larger ratio of sur-
face area to body mass.
The lipid-rich vehicle formulation used in this product
has been shown to repair the skin barrier function as
evidenced by improvement in transepidermal water loss
after a standardized insult with sodium lauryl sulfate (7).
A vehicle, in addition to having general skin care effects,
can also affect the amount of drug delivered to the
cutaneous target and the amount of drug available for
systemic absorption. To assess the potential for systemic
safety concerns, the adrenal effects of this topical for-
mulationof 0.1%hydrocortisone butyrate in a lipid-rich,
moisturizing vehicle warranted evaluation.
OBJECTIVES
The objective of this study was to evaluate the potential
for HPA axis suppression in a pediatric population that
received HB 0.1% in a lipid-rich, moisturizing cream
formulation for the treatment ofmoderate to severe AD.
Measurements of effectiveness were recorded to charac-
terize the clinical response.
MATERIALS AND METHODS
This was an open-label, multicenter study to evaluate
the potential adrenal suppressive effects of topically
applied hydrocortisone butyrate 0.1% in a lipid-enriched
cream (Locoid Lipocream; Ferndale Laboratories, Inc.,
Ferndale, MI). Conditions that assured a significant
exposure to the topical preparation included three daily
applications over a minimum body surface area of 25%.
The duration of treatment was for a maximum of
4 weeks. The open label nature of this design as well as
the three times daily use (package insert provides for 2 to
3·/day) over a 4-week period are typical FDA require-
ments for a study of this type to assure maximal adrenal
challenge to the therapy. In those subjects noted to be
clear at 3 weeks, treatment was discontinued early.
Healthy boys and girls with stable AD, 5–12 years of age
were eligible for enrollment in the study. Prior to en-
rollment, parents or guardians provided written in-
formed consents, and subjects 7–12 years of age
provided written informed assent.
The use of systemic corticosteroids, immunomodu-
lators, PUVAtherapy, or antimetaboliteswithin 4 weeks
prior to entry into the study was prohibited. Likewise,
use of topical AD therapies (including corticosteroids),
exclusive of emollients, within 2 weeks of entry was
prohibited. Stable maintenance therapy with oral anti-
histamines or asthma medications was permitted. A
medical history and physician examination were per-
formed to assure compliance with the entry criteria. Pre-
entry urine pregnancy tests were conducted for girls
11 years of age or older, to exclude pregnant subjects
from the study. Vital signs and standard laboratory tests
including chemistry, hematology, and urology were
performed at baseline (day 1) and end-of-treatment (day
22 or 29, as appropriate).
Subjects who met the entry criteria at day 1 were
scheduled for follow-upweekly evaluations at days 8, 15,
22, and 29.A seven-point Physician’sGlobalAssessment
(PGA) of overall disease severity (0 ¼ clear; 1 ¼ just
perceptible/almost cleared; 2 ¼ mild; 3 ¼ moderate;
4 ¼ marked; 5 ¼ severe; 6 ¼ extreme) was used to
determine the criteria for entry into the study, i.e., a
minimum entry score equal to or more than 3, and to
assess clinical improvement at each of the subsequent
visits. A four-point scoring system (0 ¼ none; 1 ¼ mild;
2 ¼ moderate; 3 ¼ severe) of the severity of individual
signswas recorded at each visit for erythema, infiltration/
papulation, excoriation, lichenification, oozing/crusting,
and scaling. Pruritus severity also utilized a four-point
system. Descriptions of interference with activities of
daily life were used to define pruritus scores. The per-
centage of body surface area (%BSA) involvement was
recorded at each visit. All adverse events reported during
the course of the study were recorded and evaluated.
Cortrosyn (cosyntropin for injection), a synthetic
analog of adrenal corticotrophic hormone, was used to
challenge the responsiveness of the adrenal gland. The
cosyntropin stimulation test (CST) with a 30 minute
post-injection assessment was first performed on day 1
before the initiation of treatment, and then again at the
end-of-treatment. A normal adrenal response was
defined as a post-stimulation cortisol level greater than
18 lg/dL (8).
All statistical processing was performed using SAS
software (SAS Institute Inc., Cary, NC). Descriptive
statistics, i.e., means, standard deviations, ranges, were
used for data presentation. No formal hypothesis testing
was performed for this open-label study.
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RESULTS
Twenty-one subjects were enrolled into the study, with
one lost to follow-up after the day 1 baseline visit. The
remaining 20 subjects completed the study. Baseline
demographic and disease severity information is pre-
sented in Table 1.
Two subjects whose condition cleared and remained
cleared at the day 22 visit satisfied the protocol condi-
tions for successful outcome, and after their end-of-
treatment CST, ended their participation in the study.
The remaining subjects (18/20) completed a full 4 weeks
(28 days) of treatment. None of the 20 subjects tested
with cosyntropin stimulationwas found to be suppressed
at the end-of-treatment with hydrocortisone butyrate
0.1% (Table 2).
Physician Global Assessment scores and sign and
symptom scores improved (Fig. 1). The final scores
(PGA ¼ 0) of the two subjects who completed the study
after 3 weeks were carried forward and included in the
day 29 results. The figure shows a progression of
improvement over the 3- to 4-week treatment periodwith
48% of the subjects cleared or almost cleared at week 2,
and 80% at week 4.
The changes in %BSA involvement and signs and
symptoms of AD are dramatic and consistent with the
improvement seen in the PGA as shown in Fig. 1 and
Table 3.
The treatment was well tolerated. No changes in vital
signs or in chemistry, hematology, or urology laboratory
tests were observed. Adverse events that were judged to
be related to the use of drug were reported in two sub-
jects: onewithamild, transient burningat the application
site during the first dayof use, and the secondwith a tinea
corporis infection.
DISCUSSION
An evaluation of the potential for systemic effects of
topically applied corticosteroids is an important consid-
eration in the selection of the therapeutic agent to be used
in treating pediatric populations. Vasoconstrictor testing
(VC assay) is typically performed to characterize the
relative potency of these therapies, but the degree of
vasoconstriction is a pharmacodynamic indicator of the
local cutaneous activity that may or may not correlate
with the potential for systemic effects.Directmeasures of
systemic activity such as HPA-axis suppression studies
are necessary to assess the potential for systemic toxicity.
TABLE 1. Demographics and Disease Severity
Age (years)







Black/African American 4 (20%)
Asian 2 (10%)
Hawaiian or Pacific Islander 1 (5%)
Weight (kg)
Mean (±SD) 32 (9.8)
Range 18–54
Height (cm)
Mean (±SD) 132 (13.8)
Range 105–151
%BSA involvement






TABLE 2. Cosyntropin Stimulation Tests
Mean cortisol concentration (lg/dL, ±SD)
Pre-stimulation Post-stimulation
Baseline 15.8 (7.0) 28.3 (5.5)
















Figure 1. Physician’s Global Assessment: percentage of
subjects cleared and almost cleared.





%BSA involvement 50 (17) 13 (20)
Pruritus 2.4 (0.6) 0.5 (0.7)
Erythema 1.8 (0.8) 0.5 (0.6)
Infiltration/papulation 2.1 (0.5) 0.8 (0.9)
Lichenification 2.0 (0.7) 0.6 (0.8)
Excoriation 2.0 (0.7) 0.3 (0.6)
Scaling 1.7 (0.6) 0.4 (0.7)
Oozing/crusting 0.9 (0.7) 0.1 (0.3)
*Standard deviations noted in parentheses.
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The systemic potency of a topical corticosteroid is
dependent not onlyon the amount, kinetics, and inherent
potency of the molecular entity that enters the systemic
circulation, but also on the topical vehicle. The vehicle
can play a major role in determining the transcutaneous
absorption of the active agent. The lipid-rich, emollient
cream vehicle used in this formulation of hydrocortisone
butyrate 0.1% was engineered to optimize both its
moisturizing potential and the delivery of the active
moiety into the skin, while maintaining the cosmetic
attributes that make creams popular. A double-blind
study of this formulation compared with other com-
monly used midpotency agents in the treatment of
atopic and hand dermatitis demonstrated a patient
preference for the lipid-enriched formulation (9).
The primary objective of this study was to assess the
risk of adrenal suppression with this 0.01% hydrocorti-
sone butyrate formulation. Twenty AD subjects, aged
5–12, with a mean BSA of 50% were treated for up to
4 weeks. None of the subjects demonstrated adrenal
suppression, based upon Cortrosyn stimulation test-
ing, at the end of the treatment period. No local side
effects such as thinning, striae, or telangectasia that are
associated with prolonged use of topical corticosteroids
were reported and the subjects also demonstrated signi-
ficant clinical improvement. The relevance of these
findings for children below 5 years of age, because of
difference in bodymass/surface area ratios, remains to be
determined.
CONCLUSIONS
Hydrocortisone butyrate 0.1% formulated in a lipid-
enriched, emollient vehicle base, appears to be safe, both
systemically and locally, for continuous daily adminis-
tration over a 4-weekduration of therapy in apopulation
as young as 5 years of age. In particular, in this study,
undermaximal use conditions over a 4-week period there
was no evidence of clinical or laboratory adrenal sup-
pression or local topical steroid side effects identified in
any subject. All subjects in this study retained normal
adrenal function as demonstrated by CST testing.
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